
    
      Primary Objective is to determine the efficacy, as measured by overall response rate on the
      basis of Revised Response Criteria for Malignant Lymphoma, of SyB L-0501 at 120 mg/m^2/day on
      Day 2 and Day 3 in combination with rituximab at 375 mg/m^2 on Day 1 of each 21-day cycle in
      patients with recurrent/relapsed diffuse large B-cell lymphoma.
    
  